Edition:
United States

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

358.71USD
20 Jul 2018
Change (% chg)

$0.60 (+0.17%)
Prev Close
$358.11
Open
$358.35
Day's High
$360.50
Day's Low
$356.61
Volume
721,208
Avg. Vol
676,017
52-wk High
$370.53
52-wk Low
$249.24

Chart for

About

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis... (more)

Overall

Beta: 0.92
Market Cap(Mil.): $75,564.05
Shares Outstanding(Mil.): 211.01
Dividend: --
Yield (%): --

Financials

  BIIB.OQ Industry Sector
P/E (TTM): 18.36 29.12 33.34
EPS (TTM): 19.54 -- --
ROI: 20.73 13.60 13.18
ROE: 32.41 15.30 15.09

U.S. jobs growth lifts Wall Street, offsetting tariffs

NEW YORK U.S. stocks climbed on Friday, with the S&P 500 and the Nasdaq hitting their highest levels in two weeks, as strong U.S. jobs growth blunted the impact of an escalating U.S.-China trade dispute. | Video

Jul 06 2018

CORRECTED-US STOCKS-U.S. jobs growth lifts Wall Street, offsetting tariffs

NEW YORK, July 6 U.S. stocks climbed on Friday, with the S&P 500 and the Nasdaq hitting their highest levels in two weeks, as strong U.S. jobs growth blunted the impact of an escalating U.S.-China trade dispute.

Jul 06 2018

US STOCKS-Wall Street buoyed by U.S. jobs growth despite tariffs

* Indexes up: Dow 0.6 pct, S&P 0.9 pct, Nasdaq 1.3 pct (Updates to late afternoon, changes byline, adds NEW YORK to dateline)

Jul 06 2018

US STOCKS-Strong U.S. jobs growth helps Wall Street overlook trade worries

* Indexes up: Dow 0.56 pct, S&P 0.88 pct, Nasdaq 1.27 pct (Updates to early afternoon)

Jul 06 2018

US STOCKS-Wall St rises as strong jobs data offsets trade worries

* Indexes up: Dow 0.37 pct, S&P 0.64 pct, Nasdaq 0.88 pct (Changes comment, adds details; updates prices)

Jul 06 2018

Biogen's Alzheimer's drug succeeds in mid-stage trial

July 5 Japanese drugmaker Eisai Co and Biogen Inc said on Thursday that the final analysis of a mid-stage trial of their Alzheimer's drug showed positive results for patients who received the highest dose.

Jul 05 2018

Biogen exercises call option to boost stake in Samsung Bioepis

SEOUL Biogen said it had exercised its option to purchase additional shares of biopharma developer Samsung Bioepis Co Ltd, a joint venture established in 2012 by Samsung BioLogics Co Ltd and Biogen.

Jun 28 2018

CORRECTED-Biogen exercises call option to boost stake in Samsung Bioepis

* Matter has bearing in regulatory scrutiny into BioLogics-sources

Jun 28 2018

Samsung BioLogics said JV partner Biogen to exercise option by late June

SEOUL, May 18 Samsung BioLogics said on Friday that its joint venture partner Biogen would exercise its call option to increase its stake to 50 pct minus one share in Samsung Bioepis.

May 17 2018

Accounting concerns wipe $6 billion off Samsung BioLogics market value

SEOUL South Korean biotech drug manufacturer Samsung BioLogics Co Ltd lost almost $6 billion in market value on Wednesday in its biggest intra-day share drop, after the country's financial watchdog said it breached accounting rules.

May 02 2018

Competitors

Earnings vs. Estimates